BioSpace News Archive

American Bio Medica Corporation announced it has entered into a purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.

Aytu BioScience, Inc. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions.

XOMA Corporation announced the pricing of its underwritten registered public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share at an initial public offering price of $25.00 per share, raising gross proceeds of $22.0 million before deducting underwriting discounts, the structuring fee and other estimated offering expenses.

- Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has accepte

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first patient has been successfully enrolled a

The Supreme Court of the United States issued a decision that allows state legislatures to regulate abuses of corporate healthcare middlemen, called Pharmacy Benefit Managers

CognitiveCare, a bioinformatics company and pioneer in the early detection of diseases, today announced that Sheena Gill has been appointed as Executive Vice President and Chief Growth Officer, and Sri Valavala as Chief Technology Officer.

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock at a public offering price of $45.25 per share.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the pricing of its public offering of 6,000,000 ordinary shares at an effective offering price to the public of $2.50 per share.

Aytu BioScience, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4,166,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions.